Two treatment regimens for metastatic soft-tissue sarcomas were compared in a randomized trial in the cooperative group setting. Histopathologic diagnosis was affirmed by pathology reference panel review in 72% of the 347 patients. In 21% of patients, the reference panel affirmed the diagnosis of so
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
β Scribed by D'Adamo, D. R.
- Book ID
- 125502540
- Publisher
- American Society of Clinical Oncology
- Year
- 2005
- Tongue
- English
- Weight
- 365 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0732-183X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
In a phase II study, 16 adult patients with locally advanced or metastatic soft tissue sarcomas were treated with i.v. infusions of ifosfamide/mesna 5 g/m2 plus i.v. doxorubicin 40 mg/m2. Courses were given every 3 weeks up to a maximum of six courses in responding patients. Six patients (37.5%) had
## Abstract ## BACKGROUND The objective of this study was to assess the efficacy and toxicity of the imidazotetrazine derivative temozolomide for patients with unresectable or metastatic soft tissue sarcoma. ## METHODS Twentyβfive of 26 patients were eligible and assessable for toxicity and resp